Should journals stop publishing research funded by the industry?
woensdag, 15 januari 2014 - Categorie: Berichten Internationaal
Should journals stop publishing research funded by the drug industry?
Bron: www.bmj.com/content/348/bmj.g171 .
14 jan. 2014
BMJ 2014; 348 doi: dx.doi.org/10.1136/bmj.g171 (Published 14 January 2014)
Cite this as: BMJ 2014;348:g171
The BMJ no longer publishes research funded by tobacco companies. Richard Smith and Peter Gøtzsche say that research funded by drug companies is also flawed and published to encourage sales, but Trish Groves says that the industries are fundamentally different and that moves are afoot to increase integrity
Yes— Richard Smith and Peter C Gøtzsche
The BMJ and its sibling journals have stopped publishing research funded by the tobacco industry for two main reasons: the research is corrupted and the companies publish their research to advance their commercial aims, oblivious of the harm they do.1 But these arguments apply even more strongly to research funded by the drug industry, and we suggest there is a better way to communicate the results of trials that would be safer for patients.
Prescribed drugs are the third leading cause of death, partly because of flaws in the evidence published in journals. We have long known that clinical trials funded by the drug industry are much more likely than publicly funded trials to produce results favourable to the company.2 The reason is obvious. The difference between an honest and a less than honest data analysis can be worth billions of euros, and the fraudulent trials of some cyclo-oxygenase-2 inhibitors for arthritis and selective serotonin reuptake inhibitors for depression are good examples.3 4 5
Industry cannot be trusted
There are many clever ways in which companies manipulate their research,6 and two recently published books give dozens of examples.3 7 Flaws in the coding of adverse events can distort results without leaving any trace of what has happened, as we cannot get access to the raw data the drug companies hold. Three large trials of prasugrel, rosiglitazone, and ticagrelor made by Daiichi Sankyo and Eli Lilly, GlaxoSmithKline, and AstraZeneca, respectively, published in the New England Journal of Medicine were shown to be …
Een geweldig besluit van het BMJ, dit besluit om niet te publiceren zou ditect toegepast kunnen worden op door de Telecomindustrie gefinancierd onderzoek naar de biologische, mogelijk schadelijke, effecten van EMV voor de gezondheid..
Lees verder in de categorie Berichten Internationaal | Terug naar homepage | Lees de introductie